About Conmind

About Us

Established in 2020 in Shenzhen, China, Conmind Medical specializes in the innovation, research and development, production, and sales of advanced medical devices for neurointervention and structural heart disease. We aim to provide innovative, safe, and effective treatment solutions for cardiac, neurovascular, and vascular conditions, serving healthcare professionals and patients worldwide.

With a strategic focus on integrated “Heart and Brain” treatment, our products cover neurointervention and structural heart disease. We hold over 200 patents globally and operate a CNAS-certified lab, advanced cleanrooms, and state-of-the-art manufacturing facilities. Our experienced R&D and sales teams, combined with our strengths in precision manufacturing and quality management, set us apart in the industry.

Conmind is dedicated to meeting the needs of healthcare providers and patients, shaping a new model in the interventional medical device field by integrating medical practice with engineering innovation. Our vision is to be a global leader in providing trusted and innovative interventional solutions.

200+

Employees Worldwide

200+

Patents Filed Globally

20+

Countries and Regions

200+

Hospitals with Product Access


Mission

To deliver safe, effective, and innovative neurointerventional and cardiac interventional devices, enhancing care for healthcare professionals and patients globally.

Vision

To establish ourselves as a global leader in integrated “Heart and Brain innovative solutions.

Values

Results-Driven, Immediate Action


公司结构

Conlife Medical

Neurointervention

Focused on the R&D, production, and sales of neurointerventional products. The company is equipped with cutting-edge labs, state-of-the-art cleanrooms, and comprehensive medical device manufacturing facilities. With a strong R&D and sales team, Conlife Med excels in the core development and precision manufacturing of neurointerventional products, consistently making innovative breakthroughs in the neurovascular field.

Halocinch Medical

Cardiac Intervention

Specializes in structural heart disease technologies, particularly mitral valve repair and cardiogenic stroke prevention. Committed to accelerating the application of breakthrough interventional devices in research and clinical settings. The company boasts independent R&D and production facilities, a CNAS-certified lab, cleanrooms, and comprehensive manufacturing capabilities. Committed to innovation, quality, clinical relevance, and improving patient outcomes, Halocinch Med upholds a mission to enhance cardiac care globally.

Newheart Medical

Animal Healthcare

Focused on pioneering interventional treatment for small animals, Newheart Med develops innovative devices and serves as a training center for small animal cardiac interventions. We collaborates with clinical centers and equipment manufacturers to share advanced solutions, and aims to lead the animal interventional therapy industry and explore a more professional, standardized, and healthier future for animal healthcare.

Conmind Medical (Zhuhai)

Mass Production Base

Serving as the cornerstone for the commercialization and mass production of our products, the Zhuhai base is designed and constructed in accordance with international standards. It plays a crucial role in supporting the rapid market growth and demand for Conmind’s innovative medical solutions.

Our Journey

March 2020

Conmind Medical was established.

Conmind Medical was established.

September 2020

A 2,500-square-meter cleanroom facility was officially put into operation, accelerating R&D projects.

December 2020

An additional 2300-square-meter cleanroom facility was brought into use.

June 2022

Obtained the Medical Device Operation License (Class III) in China.

Obtained the Medical Device Operation License (Class III) in China.

August 2022

Launched the first human clinical trial with the J-Tube™ Flow Diverter Stent, officially starting patient enrollment.

Launched the first human clinical trial with the J-Tube™ Flow Diverter Stent, officially starting patient enrollment.

September 2022

4 neurointerventional products received NMPA registration (China).

4 neurointerventional products received NMPA registration (China).

December 2022

Conlife Med was recognized as a National High-Tech Enterprise.

Conlife Med was recognized as a National High-Tech Enterprise.

May 2023

Halocinch Med received ISO 13485 certification for its medical device quality management system.

Halocinch Med received ISO 13485 certification for its medical device quality management system.

September 2023

Conmind Med (Zhuhai) was established, marking the beginning of our commercial-scale production base to prepare for product commercialization.

Conmind Med (Zhuhai) was established, marking the beginning of our commercial-scale production base to prepare for product commercialization.

September 2023

2 neurointerventional product registration certificates were approved: Campsis™ 2.7F Microcatheter and Fringe® Support Catheter received NMPA registration (China).

October 2023

Conlife Med was recognized as an “Innovative SME” by the Shenzhen government.

Conlife Med was recognized as an “Innovative SME” by the Shenzhen government.

October 2023

Conlife Med obtained ISO 13485 quality management system certification.

Conlife Med obtained ISO 13485 quality management system certification.

November 2023

HaloChord® Transapical Mitral Chordal Repair System was approved under China’s Special Review Procedure for Innovative Medical Devices.

HaloChord® Transapical Mitral Chordal Repair System was approved under China’s Special Review Procedure for Innovative Medical Devices.

April 2024

Crassula™ Intracranial Coiling Embolization System received NMPA approval for market launch.

Crassula™ Intracranial Coiling Embolization System received NMPA approval for market launch.

June 2024

Halostitch® Transcatheter PFO Closure System initiated multicenter clinical trials, enrolling the first patient. This is the first technology in China capable of closing PFO using a suturing technique via femoral vein access and the world’s first PFO interventional procedure completed under zero-radiation ultrasound guidance.

June 2024

Kapflex™ Intracranial Stent System for Neurointervention completed its first patient enrollment in human clinical trials.

Act as a leading global healthcare provider trusted by doctors and patients

Core Team

Zeng Zheng

Previously served as Associate Chief Physician at the Fuwai Hospital CUMA & PUMC and was the Founder and Chairman of Starway Medical Technology, Inc.
Awards received:
First Prize in the Ministry of Health Science and Technology Progress Award (China) for research on cardiovascular interventional radiology technology and application Second Prize in the National Science and Technology Progress Award (China) for research on cardiovascular interventional technology and application
Second Prize in the National Science and Technology Progress Award (China) for research and application of new interventional techniques for structural heart disease

Zeng Tian

With a forward-thinking vision and extensive expert and social resources, Zeng Tian is the co-founder of Conlife and Halocinch. Previously served as Sales Director at Starway Medical Technology, Inc., where he established a comprehensive sales market system, successfully capturing 30% of the congenital heart disease market share and 70% of the PFO market share

Intellectual Property

产权证书
产权证书
产权证书
产权证书
产权证书
产权证书
产权证书
产权证书
产权证书
产权证书
产权证书
产权证书
产权证书
产权证书
产权证书
产权证书
产权证书
产权证书
产权证书
产权证书
产权证书
产权证书
产权证书
产权证书
产权证书
产权证书
产权证书
产权证书
产权证书
产权证书
产权证书
产权证书
产权证书
产权证书
产权证书
产权证书
产权证书
产权证书
产权证书